Genflow Biosciences PLC (LON: GENF) said it made solid operational progress during 2025, advancing multiple programmes across aging, metabolic disease and gene therapy, while laying the groundwork for a more focused strategy in 2026.
The company reported encouraging progress in its canine ageing study, GF-1004, with no adverse events observed during the dosing phase. An initial efficacy readout is expected in the first quarter of 2026.
Genflow also advanced its MASH programme, GF-1002, repositioning the asset towards advanced fibrosis and generating preclinical data supporting potential hepatocellular carcinoma prevention. The group is additionally exploring mRNA and lipid nanoparticle delivery technologies to support future development.
During the year, Genflow expanded into ophthalmology through a SIRT6-based gene therapy targeting glaucoma, addressing a market estimated at $12–14bn by the early 2030s. Progress was also made across its sarcopenia programme and the ExoFastTrack initiative.
Looking ahead, the company said it plans to streamline its pipeline in 2026, prioritising programmes with the strongest data packages and partner interest, while pursuing early-stage licensing opportunities to generate non-dilutive funding.
Looking Ahead to 2026
As we move into 2026, we do so with confidence, discipline, and a clear strategic focus. The coming year will emphasize rationalization of our pipeline, prioritizing programs with the strongest data, clearest paths to value creation, and highest partner interest. Central to this strategy will be the pursuit of early-stage licensing and collaboration agreements designed to generate non-dilutive funding, validate our platform externally, and support continued development without undue capital strain.
With multiple upcoming data readouts, an expanding partner network, and a maturing intellectual property position, we believe Genflow is well positioned to enter its next phase of growth. We remain committed to scientific excellence, capital efficiency, and long-term value creation as we work to translate our longevity platform into meaningful therapies.
Thank you for your continued support and confidence in Genflow.
Dr. Eric Leire
Founder & Chief Executive Officer
